Intellia Therapeutics Stock Alert: Intellia Investors with Financial Losses Encouraged to Contact Kehoe Law Firm, P.C. - NTLA

PHILADELPHIA, PA / ACCESS Newswire / November 7, 2025 / Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ:NTLA).

On October 27, 2025, Intellia reported that ". . . it has temporarily paused dosing and screening in the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials for nexiguran ziclumeran ('nex-z')."

Intellia stated that "[t]his action follows a report on October 24, 2025 of Grade 4 liver transaminases and increased total bilirubin in a patient who was dosed with nex-z in the MAGNITUDE trial on September 30, 2025, meeting the trial's protocol-defined pausing criteria."

On this news, Intellia's stock price fell $10.81 per share, or 42.23%, to close at $14.79 per share on October 27, 2025.

On October 29, 2025, Intellia reported that the FDA ". . . verbally informed the Company that the FDA has placed a clinical hold on the Investigational New Drug applications for the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials for nexiguran ziclumeran ('nex-z'). [The] FDA indicated that it would provide a formal Clinical Hold Letter within 30 calendar days."

The Company also reported that the ". . . clinical hold follows the previously disclosed report of Grade 4 liver transaminases and increased total bilirubin in a patient who was dosed with nex-z in the MAGNITUDE trial. As previously announced on October 27, 2025, the Company had temporarily paused dosing and screening in the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials for nex-z based on the MAGNITUDE trial's protocol-defined pausing criteria."

On this news after the market closed on October 29, 2025, Intellia's stock price was down more than 16%.

And on the news of the Company's Q3 2025 financial results and updates regarding MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z, Intellia's stock price was down more than 26% during intraday trading on November 7, 2026.

Investors of Intellia stock with financial losses are encouraged to complete Kehoe Law Firm's Stockholder Information Request Form or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, myarnoff@kehoelawfirm.com, info@kehoelawfirm.com, to learn more about the investigation and receive a free, no-obligation evaluation of potential legal claims.

Additional information is available at https://kehoelawfirm.com/intellia-therapeutics-ntla/.

ABOUT KEHOE LAW FIRM, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

This press release may constitute attorney advertising.

SOURCE: Kehoe Law Firm, P.C.